15 year experience of tacrolimus application in medical practice

Cover Page


Cite item

Full Text

Abstract

The review presents modern literature data on the use of tacrolimus in medical practice. The results of national and international research on the effectiveness and safety of the drug at various dermatoses are presented.

About the authors

Y. S. Kondratyeva

Altai Medical State University

Author for correspondence.
Email: julia_ jsk@mail.ru
Россия

O. A. Kokina

Altai Medical State University

Email: noemail@neicon.ru
Россия

A. A. Vedler

Altai Medical State University

Email: noemail@neicon.ru
Россия

References

  1. Mashkovskij M.D. Preparaty, korrigirujushhie processy immuniteta (immunomoduljatory, immunokorrektory). V: Mashkovskij M.D. Lekarstvennye sredstva. M., 1993. T. 2. s. 192-209.
  2. Leskov V.P. Immunostimuljatory. Allergija, astma i klinicheskaja immunologija 1999; (4): 12-25.
  3. Bakulev A.L. Takrolimus: 10 let uspeshnogo primenenija v klinicheskoj praktike. Vestn dermatol venerol 2010; (6): 23-28
  4. Ruzicka T., Assmann T., Homey B. Tacrolimus: The drug for the turn of the millennium? Arch Dermatol 1999; 135 (5): 574-580.
  5. Lawrence I.D. Tacrolimus (FK506): experience in dermatology. Dermatol Ther 1998; (5): 74-84.
  6. Michel G., Kemeny L., Homey B., Ruzicka T. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 1996; 17 (3): 106-108.
  7. Nghiem P., Pearson G., Langley R.G. Tacrolimus and pimecrolimus: From clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. Journal of the American Academy of Dermatology 2002; 46 (2): 228-241.
  8. Steroid-free,tacrolimus-basiliximab immunosuppression in pediatric liver tran-splantation:Clinical and pharmacoeconomic study in
  9. children / Gras J.M., Gerkens S., Beguin C. et al. Liver Transpl 2008; 14: 469-477.
  10. Instrukcija po medicinskomu primeneniju preparata Protopik. LSR-001885/10-120310. [Инструкция по медицинскому применению препарата Протопик. ЛсР-001885/10-120310.]
  11. Bieber T. Topical tacrolimus (FK506): a new milestone in the management of atopic dermatitis. J Allergy Clin Immunol 1998; 102: 555-557.
  12. Reitamo S., Rissanen J., Remitz A. et al. Tacrolimus ointment does not affect collagen synthesis: resultsof a single-center randomized trial. J Invest Dermatol 1998; 111: 396-398.
  13. Laurema A.I., Granlund H., Reitamo S. Use of the newer immunosuppressive agents in dermatology. Bio Drugs 1997; 8: 96-106.
  14. Baumgart D.C., Silverberg N.B., Lin P. et al. Tacrolimus ointment promotes repigmentation of viiligo in children: a review of 57 cases. J Am Acad Dermatol 2004; 51 (5): 760-766.
  15. Borisenko O.V. Bezopasnost topicheskikh ingibitorov kal'tsinevrina. Mezhdunarodnyy zhurnal meditsinskoy praktiki 2006; 5 (4): 69-73
  16. Munzenberger P.J., Montejo J.M. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Pharmacotherapy 2007; 27 (7): 1020-1028.
  17. Fajzullina E.V., Fajzullin V.A., Fajzullin Ja.V. Takrolimus pri lechenii atopicheskogo dermatita. Klin dermatol venerol 2012; 10 (3): 56-61.
  18. Korsunskaja I.M., Nevozinskaja Z.A., Mel'nichenko O.O. Takrolimus v topicheskoj terapii atopicheskogo dermatita. Klin dermatol venerol 2011; 9 (5): 86-91.
  19. Ruzicka T., Bieber T., Schöpf E. et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337 (12): 816-821.
  20. Hanifin J.M., Ling M.R., Langley R. et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001; 44 (1 Suppl): S28-38.
  21. Paller A., Eichenfield L.F., Leung D.Y. et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44 (1 Suppl): S47-57.
  22. Reitamo S., Harper J., Bos J.D. et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol 2004; 150 (3): 554-562.
  23. Arkwright P.D., Gillespie M.C., Ewing C.I., David T.J. Blinded side-to-side comparison of topical corticosteroid and tacrolimus ointment in children with moderate to severe atopic dermatitis. Clin Exp Dermatol 2007; 32 (2): 145-147.
  24. Kim K.H., Kono T. Over view of efficacy and safety of tacrolimus ointment in patients with atopic dermatitis in Asia and other areas. Int J Dermatol 2011; 50 (9): 1153-1161.
  25. Karvonen S.L., Rasanen L., Cunliffe W.J. et al. Delayed hypersensitivity to Propionibacterium acnes in patients with severe nodular acne and acne fulminans. DerIatology 1998; 189 (4): 344-349.
  26. Beck L.A. The efficacy and safety of tacrolimus ointment: a clinical review. J Am Acad Dermatol 2005; 53 (2 Suppl. 2): S165-170.
  27. Reitamo S., Wollenberg A., Schopf E. et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol 2000; 136 (8): 999-1006.
  28. Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002; 109 (3): 547-555.
  29. Reitamo S., Van Leent E.J., Ho V. et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109 (3): 539-546.
  30. Paller A.S., Lebwohl M., Fleischer A.B. et al. Tacrolimus Ointment is more effective than Pimecrolimus cream with a similar safety profile in the treatment of Atopic Dermatitis: Results from 3 randomized. Comparative Studies. JAAD 2005; 52 (5): 810-822.
  31. Lysenko O.V., Iglikov V.A., Zagoskina E.A., Podivilova Ju.S. Ispol'zovanie 0,1% mazi takrolimus v terapii bol'nyh atopicheskim dermatitom, rezistentnym k drugim vidam lechenija. Klin dermatol venerol 2014; (3): 33-39.
  32. Nakagawa H., Etoh T., Ishibashi Y. et al. Effects of tacrolimus (FK506) ointment for facial atopic dermatitis. Madrid, Spain, 24 June 1995. XVI European Congress of Allergology and Clinical Immonology. Conference Proceeding. Madrid 1995; 761-764.
  33. Aoyama H., Tabata N., Tanaka M. et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995; 133 (3): 494-496.
  34. Drake L., Prendergast M., Maher R. et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol 2001; 44 (1 Suppl): S65-S72.
  35. Remitz A., Reitamo S. Long-term safety of tacrolimus ointment in atopic dermatitis. Expert Opin Drug Saf 2009; 8 (4): 501-506.
  36. Yan J., Chen S.L., Wang X.L., Zhou W., Wang F.S. Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol. 2008; 25 (1): 117-120.
  37. Lebwohl M., Freeman A.K., Chapman M.S. et al. Tacrolimus ointment is effective for facial and intertriginous psoriasis. Acad Dermatol 2004; 51 (5): 723-730.
  38. Clayton T.H., Harrison P.V., Nicholls R., Delap M. Topical tacrolimus for facial psoriasis. Br J Dermatol 2003; 49: 419-420.
  39. Yamamoto T., Nishioka K. Topical tacrolimus is effective for facial lesions of psoriasis. Acta Dermatol Venereol 2000; 80 (6): P. 451.
  40. Nagao K., Ishiko A., Yokoyama T. et al. A case of generalized pustular psoriasis treated with topical tacrolimus. Arch Dermatol 2003; 139 (9): 1219.
  41. Theis D., Hagemann T., Dederer H. et al. Successful treatment of acrodermatitis continua suppurativa with topical tacrolimus 0.1% ointment. Br J Dermatol 2004; 150 (6): 1194-1197.
  42. Ribero S., Stieger M., Quaglino P. et al. Efficacy of topical tacrolimus for oral lichen planus: real-life experience in a retrospective cohort of patients with a review of the literature. J Eur Acad Dermatol Venereol. 2015; 29 (6): 1107-1113.
  43. Meshkinpour A., Sun J., Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol 2003; 49 (1): 145-147.
  44. Hengge U.R. Off-label indications for topical tacrolimus. Hautarzt Vol. 64 Issue 10 ISSN 0017-8470 Starting Page 752.
  45. Braza T.J., DiCarlo J.B., Soon S.L., McCall C.O. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an openlabel pilot study. Br J Dermatol 2003; 148 (6): 1242-1244.
  46. Rigopoulos D., Ioannides D., Kalogeromitros D. et al. Treatment of seborrhoeic dermatitis. Br J Dermatol 2004; 151 (5): 1071-1075.
  47. Cavalié M., Ezzedine K., Fontas E. et al. Maintenance therapy of adult vitiligo with 0.1% tacrolimus ointment: a randomized, double blind, placebo-controlled study. J Invest Dermatol. 2015; 135 (4): 970-974.
  48. Kanwar A.J., Dogra S., Parsad D. Topical Tacrolimus for treatment of childhood vitiligo in Asians. Clin Exp Dermatol 2004; 29 (6): 589-592.
  49. Silverberg N.B., Lin P., Travis L. et al. Tacrolimus oin tment promotes repigmentation of vitiligo in children: a revi ew of 57 cases. J Am Acad Dermatol 2004; 51 (5): 760-766.
  50. Tanghetti E.A. Tacrolimus ointment 0.1% produces repig mentation in patients with vitiligo: results of a prospective pati ents series. Cutis 2003; 71 (2): 158-162.
  51. Lepe V., Moncada B., Castanedo-Cazares J.P. et al. A do ubleblind randomized trial of 0.1% Tacrolimus vs 0.05% clobe tasol for the treatment of childhood vitiligo. Arch Dermatol 2003; 139 (5): 581-585.
  52. Grimes P.E., Morris R., Avaniss-Aghajani E. et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004; 51 (1): 52-61.
  53. Kawalek A.Z., Spencer J.M., Phelps R.G. Combined excimer laser and topical Tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004; 30 (2): 130-135.
  54. Passeron T., Ostovari N., Zakaria W. et al. Topical tacrolimus and the 308nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004; 140 (9): 1065-1069.
  55. Mayoral F.A., Gonzalez C., Shah N.S., Arciniegas C. Repigmentation of vitiligo with Pimecrolimus cream: a case- report. Dermatology 2003; 207 (3): 322-323.
  56. Coskun B., Saral Y., Turgut D. Topical 0.05% clobetasol propionate vs 1% Pimecrolimus ointment in vitiligo. Eur J Dermatol 2005; 15 (2): 88-91.
  57. Monahov K.N. Vozmozhnosti primeneniya topicheskih ingibitorov kalcinevrina v dermatologii. Ehffektivnaja farmakoterapija. Dermatovenerol dermatokosmetol 2015; 1 (9).
  58. Böhm M., Gaubitz M., Luger T.A. et al. Topical tacrolimus as a therapeutic adjunct in patients with cutaneous lupus erythematosus. A report of three cases. Dermatology 2003; 207 (4): 381-385.
  59. Druke A., Gambichler T., Altmeyer P. et al. 0.1% tacrolimus ointment in a patient with subacute cutaneous lupus erythematosus. J Dermatolog Treat 2004; 15 (1): 63-64.
  60. Lampropoulos C.E., Sangle S., Harrison P. et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43 (11): 1383-1385.
  61. Yoshimasu T., Ohtani T., Sakamoto T. et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12 (1): 50-52.
  62. Kanekura T., Yoshii N., Terasaki K. et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148 (2): 353-356.
  63. Kreuter A., Gambichler T., Breuckmann F. et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51 (3): 407-410.
  64. Milam E.C., Ramachandran S., Franks Jr A.G. Treatment of Scarring Alopecia in Discoid Variant of Chronic Cutaneous Lupus Erythematosus With Tacrolimus Lotion, 0.3%. JaMa Dermatol 2015; 151 (10): 1113-1116.
  65. Böhm M., Frieling U., Luger T.A., Bonsmann G. Successful treatment of anogenital lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139 (7): 922-924.
  66. Kunstfeld R., Kirnbauer R., Stingl G., Karlhofer F.M. Successful treatment of vulvar lichen sclerosus with topical tacrolimus. Arch Dermatol 2003; 139 (7): 850-852.
  67. Assmann T., Becker-Wegerich P., Grewe M. et al. Tacrolimus ointment for the treatment of vul var lichen sclerosus. J Am Acad Dermatol 2003; 48 (6): 935-937.
  68. Hodgson T.A., Malik F., Hegarty A.M., Porter S.R. Topical tacrolimus: a novel therapeutic intervention for recalcitrant labial pemphigus vulgaris. Eur J Dermatol 2003; 13 (2): 142-144.
  69. Gach J.E., Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol 2004; 29 (3): 271-272.
  70. Rabeni E.J., Cunningham N.M. Effective treatment of Hailey-Hailey disease with topical tacrolimus. J Am Acad Dermatol 2002; 47 (5): 797-798.
  71. Sand C., Thomsen H.K. Topical tacrolimus ointment is an effective therapy for Hailey-Hailey disease. Arch Dermatol 2003; 139 (11): 1401-1402.
  72. Umar S.A., Bhattacharjee P., Brodell R.T. Treatment of Hailey-Hailey disease with tacrolimus ointment and clobetasol propionate foam. J Drugs Dermatol 2004; 3 (2): 200-203.
  73. Triantafillidis, J.K. Valvi F.Z., Merikas E. Granulomatous cheilitis associated with exacerbations of Crohn’s disease: a case report patients with Crohn’s disease (CD). J Med Case Reports 2008; 2 (1): 1.
  74. Filimonkova N.N., Kascheeva Y.V., Kolbina M.S. Experience of using tacrolimus as a part of a complex therapy of atopic dermatitis. Vestn dermatol venereol 2016; 3: 118-124.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Kondratyeva Y.S., Kokina O.A., Vedler A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies